Sandimmune® to neoral® conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients

Abstract: Neoral® is a new microemulsion formulation of cyclosporin A (CsA) that has been reported to have better absorption characteristics than sandimmune®. We converted 25 long‐term pediatric renal transplant recipients with a mean age of 14.1 yr and a mean follow‐up period of 6.4 yr from sandimmune (SIM) to neoral (NEO) on a 1 : 1 basis. The mean dosage of SIM or NEO required to maintain ‘therapeutic range’ steady‐state trough levels between 100 and 200 ng/mL was similar. We compared 6‐h CsA pharmacokinetic profiles taken approximately 6 months after the conversion to NEO with the previous SIM profiles of the same patients. Generally, in the NEO profiles the time to reach the maximum concentration was shorter and the maximum concentration was higher, showing a rapid decline towards the trough‐level when compared to the previous SIM profiles. During intake of NEO the AUC0–12 h in the 12‐h profiles correlates strongly with the AUC0–6 h in the 6‐h profiles (r = 0.98), a similar finding to that which we reported previously for SIM. The median AUC0–6 h for NEO demonstrates a 70% increase compared to the median AUC0–6 h for SIM. Despite the increased drug exposure NEO was well tolerated and did not cause any apparent toxicity within the first 6 months after conversion. The CsA blood level 2 h after intake of NEO showed a higher correlation with the AUC0–12 h (r = 0.91) than the trough level (r = 0.64). The abbreviated profile based on three early sampling points and calculated by AUCPRED= 335.9 + 1.1*(C1) + 1.1*(C2) + 5.4*(C4) correlated well with the full AUC (r2 = 0.98, p < 0.0001). Mean prediction error (±SD) was 0.16% (±4.32), and in no patients did the calculated values fall outside the 10% prediction error limit. We therefore conclude that NEO exhibits a higher bioavailability in children compared to SIM without causing apparent toxicity. Monitoring of the C2 might be a better alternative for trough level monitoring in daily clinical practice. A strategy of three early sampling points (C1, C2 and C4) allows a reliable AUC0–12 h prediction and can reduce the length of observation, making it a useful and cost‐effective tool in clinical practice.

[1]  J. Barkun,et al.  Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. , 1998, Clinical transplantation.

[2]  R. Loertscher,et al.  Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. , 1998, Transplantation.

[3]  P. Hoyer.  Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. , 1998, Pediatric transplantation.

[4]  G. Clark,et al.  Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients , 1997, Pediatric Nephrology.

[5]  G. Nyberg,et al.  The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group. , 1997, Transplantation proceedings.

[6]  A. Kelles,et al.  Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  K. Schärer,et al.  Pharmacokinetics of a new microemulsion formulation of cyclosporin A (Neoral) in young patients after renal transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  R. Ettenger,et al.  Use of Neoral in pediatric renal transplantation. , 1996, Transplantation proceedings.

[9]  B. Kahan,et al.  Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. , 1996, Transplantation proceedings.

[10]  U. Vester,et al.  Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. , 1996, Transplantation proceedings.

[11]  S. Friman,et al.  A New Microemulsion Formulation of Cyclosporin , 1996, Clinical pharmacokinetics.

[12]  J. Kovarik,et al.  Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients , 1995, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  J. Alexander,et al.  Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. , 1995, Transplantation.

[14]  J. Kovarik,et al.  The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. , 1994, Transplantation proceedings.

[15]  J. Alexander,et al.  The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. , 1994, Transplantation proceedings.

[16]  C. Lin,et al.  Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients. , 1994, Transplantation proceedings.

[17]  J. Kovarik,et al.  CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS , 1994, Transplantation.

[18]  M. Englund,et al.  Ten years' experience of renal transplantation in children in the cyclosporine era. , 1993, Transplantation.

[19]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[20]  B. Kahan,et al.  Cyclosporine Monitoring in Renal Transplantation: Area Under the Curve Monitoring Is Superior to Trough‐Level Monitoring , 1989, Therapeutic drug monitoring.

[21]  Lisa Anne Hendricks,et al.  SAFETY AND TOLERABILITY OF CYCLOSPORINE AND CYCLOSPORINE MICROEMULSION DURING 18 MONTHS OF FOLLOW-UP IN STABLE RENAL TRANSPLANT RECIPIENTS , 1998 .